Aytu BioPharma’s (AYTU) treatment of Marfan syndrome, enzastaurin, received FDA orphan designation, according to a post to the agency’s site.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AYTU: